Recent Updates
Recently added Catalysts

IGM Biosciences, Inc.

IGMSFDA catalysts, PDUFA dates & pipeline intelligence
$1.27
▼ -0.03 · -2.31%

Last traded Aug 13, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IGMS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.9252W HIGH $22.50
Volume
1.62 M
Value Traded
2.07 M
Short % Float
4.31%
Days to Cover
1.0
-0.78%Week
-5.22%1 Month
+12.39%3 Month
-8.63%6 Month
-97.53%5 Year
-93.06%All Time

Cash Data

Unlock IGMS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
78.71 M
EPS (TTM)
-0.90
P/E Ratio
-
Ent. Value
-25.59 M
Total Shares
36.59 M
Float Shares
17.64 M
Insiders
72.19%
Institutions
21.92%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every IGMS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IGMS Catalyst Timeline

Dated clinical, regulatory and corporate events for IGM Biosciences, Inc.

Unlock the full IGMS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IGMS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all IGMS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
IGM-7354 Small moleculeCompletedNCT05702424Solid TumorPhase 1 COMPLETED 14May 31, 2024
Unlock the IGMS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IGMS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IGM-8444 metastatic colorectal cancerPhase 12023-06-02median progression free survival: 5.6 months; historical median progression free survival: approximately 2 months; longest observed progression free survival: beyond 16 months; patients remaining on treatment: 11 of 24; evaluable patients with bevacizumab: 17; patients remaining on study with bevacizumab: 13 of 17Read MoreIGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical DevelopmentRead More
Scroll for more · summaries link to the source press release
Unlock every IGMS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IGMS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Tahir MisbahOfficer (CHIEF FINANCIAL OFFICER)Sell -8,741 170,061 held$1.27 07/23/2025
Unlock the full IGMS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in IGMS

Fund % of Portfolio Current MV Shares Owned Activity
BAKER BROS. ADVISORS 0 % (-100 %) 4.59 M 4.10 M 0.02% ( 953.00)
Unlock every fund holding IGMS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IGMS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IGMS ownership
Insider and institutional ownership, quarter by quarter.

IGMS Short Interest

Shares sold short, counted twice a month.

4.31%
Short % of Float
of tradable shares sold short
452.1K
Shares Sold Short
+11.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
623.6K
Avg Daily Volume
the average used for days to cover
Unlock IGMS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock IGMS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IGMS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IGMS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IGMS ranks across every disease it competes in

Competitive Position is a premium feature
See how IGMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IGMS News

About IGM Biosciences, Inc.

BIOPHARMAWATCH ELITE PLUS
Trade the next IGMS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime